Biotech | July 10, 2022
WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Brings 25 years of global operations and supply chain experience to Piramal
Both manufacturing facilities are based out of Benguluru, India
Subscribe To Our Newsletter & Stay Updated
